tbuckley/cabot-search huggingface dataset:
Weight Loss and Heart Failure
Authors: Johan Sundström, Gustaf Bruze, Johan Ottosson, Claude Marcus, Ingmar Näslund, Martin Neovius
Journal: Circulation (2017)

Associations of obesity with incidence of heart failure have been observed, but the causality is uncertain. We hypothesized that gastric bypass surgery leads to a lower incidence of heart failure compared with intensive lifestyle modification in obese people.We included obese people without previous heart failure from a Swedish nationwide registry of people treated with a structured intensive lifestyle program and the Scandinavian Obesity Surgery Registry. All analyses used inverse probability weights based on baseline body mass index and a propensity score estimated from baseline variables. Treatment groups were well balanced in terms of weight, body mass index, and most potential confounders. Associations of treatment with heart failure incidence, as defined in the National Patient Register, were analyzed with Cox regression.The 25 804 gastric bypass surgery patients had on average lost 18.8 kg more weight after 1 year and 22.6 kg more after 2 years than the 13 701 lifestyle modification patients. During a median of 4.1 years, surgery patients had lower heart failure incidence than lifestyle modification patients (hazard ratio, 0.54; 95% confidence interval, 0.36-0.82). A 10-kg achieved weight loss after 1 year was related to a hazard ratio for heart failure of 0.77 (95% confidence interval, 0.60-0.97) in both treatment groups combined. Results were robust in sensitivity analyses.Gastric bypass surgery was associated with approximately one half the incidence of heart failure compared with intensive lifestyle modification in this study of 2 large nationwide registries. We also observed a graded association between increasing weight loss and decreasing risk of heart failure.
Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma.
Authors: Merrick I. Ross, Robert Hans Ingemar Andtbacka, Igor Puzanov, Mohammed M. Milhem, Frances A. Collichio, Keith A. Delman, R Dirk Noyes, Jonathan S. Zager, Lee D. Cranmer, Lynn E. Spitler, Eddy C. Hsueh, David W. Ollila, Thomas Amatruda, Lisa Chen, Jennifer L. Gansert, Howard L Kaufman
Journal: Journal of Clinical Oncology (2014)

9026 Background: T-VEC is an intralesional oncolytic immunotherapy comprising a modified HSV-type 1. In the randomized OPTiM phase 3 trial, T-VEC significantly improved DR rate (DRR, continuous partial or complete response for ≥6 mo) by 16% vs 2% and overall RR by 26% vs 6% vs subcutaneous (SC) GM-CSF in patients (pts) with advanced melanoma. We hypothesized that some pts progressed on treatment (tx) prior to DR and sought to determine how such events impacted the durability of response. Here we describe response patterns in T-VEC-treated pts with a DR. Methods: 436 pts with Stage IIIB-IV melanoma were randomized 2:1 to receive intralesional T-VEC or SC GM-CSF until clinically significant PD, intolerability, or lack of injectable lesions. Tx was to continue for at least 6 mo during which tx discontinuation for PD was not required. PD prior to response (PPR) was defined as the appearance of a new lesion or >25% increase in baseline tumor burden. Injection of new lesions was allowed. Responders were grouped as 1) PPR or 2) no PPR. PPR was grouped by a) existing lesions (± new lesions) or b) new lesions only. Pts without PPR were grouped by DR onset at ≤6 mo or >6 mo. Results: Of 48 T-VEC pts with a DR, 23 (48%) had PPR: 9 (39%) pts had PD in existing lesions (± new lesions) and 14 (61%) had new lesions only. For 25 pts with no PPR, 21 (84%) had a DR beginning within the first 6 mo. 40 (83%) of the DRs remain in remission with a median follow up of over 18.4 mo. Conclusions: Similar to other immunotherapies, PPR was common in T-VEC-treated pts. Most PPRs included the development of new lesions, thus T-VEC tx should continue through PD. The quality of DR does not seem to be negatively affected by PPR or the timing of achieving DR. These data reinforce the evolving new paradigm of response criteria when treating pts with melanoma with immunotherapeutic agents. Clinical trial information: NCT00769704.DR by PPR Status. Without PPR (n=25) With PPR (n=23) Median (Min, Max) time to DR (mo)a 3.1 (1.2, 9.5) 5.8 (1.3, 10.6) Median (Min, Max) duration of DR (mo) NE (6.2+, NE) NE (6.3, NE) DR maintained at end of follow-up, n (%)b 22 (88%) 18 (78%) aP=0.004, Wilcoxon rank sum test; bP=0.27, log rank test; NE, Not evaluable, median not reached; +censored.
Abstract 648: Comparison of the Role of Focal Firing Sources Derived from the Pulmonary Vein Region with those from the Non-Pulmonary Vein Region for the Initiation and Perpetuation of Atrial Fibrillation
Authors: Hiroshige Yamabe, Yasuaki Tanaka, Kenji Morihisa, Takashi Uemura, Koji Enomoto, Hisao Ogawa
Journal: Circulation (2008)

Background: Focal firing sources derived from the pulmonary vein (PV) have been suggested to be necessary for the initiation and perpetuation of atrial fibrillation (AF). However, it has also been ...
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Christine Parseghian, Nila Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David Fogelman, Anastasia Katsiampoura, David Menter, Robert Wolff, Cathy Eng, Michael J Overman, Alain Thierry, Gary Gallick, Scott Kopetz
Journal: Clinical Cancer Research (2017)

Purpose: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investigated in combination with FOLFOX and cetuximab.Experimental Design: We performed a phase IB/II study of 77 patients with previously treated mCRC. Primary objectives were to determine the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacodynamics, and efficacy. Using a 3 + 3 design, patients received FOLFOX6 with cetuximab and escalating doses of dasatinib (100, 150, 200 mg daily), followed by a 12-patient expansion cohort at 150 mg. Phase II studies evaluated FOLFOX plus dasatinib 100 mg in KRAS c12/13mut patients or in combination with cetuximab if KRAS c12/13WT FAK and paxillin were utilized as surrogate blood biomarkers of Src inhibition, and paired biopsies of liver metastases were obtained in patients in the expansion cohort.Results: In phase IB, the DLTs were grade 3/4 fatigue (20%) and neutropenia (23%). In phase II, grade 3/4 fatigue (23%) and pleural effusions (11%) were present. Response rates were 20% (6 of 30) in the phase IB escalation and expansion cohort and 13% (3 of 24) and 0% (0 of 23) in the KRAS c12/13WT and mutant cohorts of phase II, respectively. Median progression-free survival was 4.6, 2.3, and 2.3 months, respectively. There was no evidence of Src inhibition based on surrogate blood biomarkers or paired tumor biopsies.Conclusions: The combination of dasatinib plus FOLFOX with or without cetuximab showed only modest clinical activity in refractory colorectal cancer. This appears to be primarily due to a failure to fully inhibit Src at the achievable doses of dasatinib. The combination of dasatinib plus FOLFOX with or without cetuximab did not show meaningful clinical activity in refractory colorectal cancer due to failure to fully inhibit Src. Clin Cancer Res; 23(15); 4146-54. ©2017 AACR.
Human Papillomavirus (HPV)-Attributable Subsequent Neoplasms (SNs) After Hematopoietic Cell Transplantation (HCT) – a Potentially Preventable Outcome
Authors: J Berano Teh, Can-Lan Sun, Sharon Wilczynski, Joel Epstein, R. Spielberger, Ellie Maghami, Wendy Landier, Liton Francisco, Saro H. Armenian, Lennie Wong, Stephen J. Forman, Smita Bhatia
Journal: Blood (2012)
Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update
Authors: Thanh Ho, Juliana Perez Botero, William J Hogan, Saad S Kenderian, Naseema Gangat, Ayalew Tefferi, Roshini S Abraham, Phuong L. Nguyen, Jennifer L Oliveira, Rong He, Dong Chen, David Viswanatha, Vilmarie Rodriguez, Shakila Khan, Mrinal M Patnaik
Journal: Blood (2016)
Pooled RCTs: In sepsis, continuous (vs intermittent) antibiotic infusion reduced hospital mortality
Authors: Daniel I. Steinberg
Journal: Annals of Internal Medicine (2017)

Source Citation Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194:681-91. 26974879
Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment
Authors: Moshe E. Gatt, Izhar Hardan, Evgene Chubar, Celia Surio, Tamar Tadmor, Olga Shvez, Paulina Patachenco, Najib Dali, Shay Yeganeh, Irit Avivi
Journal: Blood (2012)
Durability of Weaning Success for Liberation from Invasive Mechanical Ventilation: An Analysis of a Nationwide Database
Authors: Sheng-Yuan Ruan, Nai-Chi Teng, Huey-Dong Wu, Shu-Ling Tsai, Cheng-Yi Wang, Chin-Pyng Wu, Chong-Jen Yu, Likwang Chen
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
The DCC Heterozygote Reduces the Latency Period and Changes the Disease Phenotype of Myeloproliferative Disease in p230BCR/ABL-Expressing Mice.
Authors: Koiti Inokuchi, Mituharu Inami, Yazhu Wang, Ayako Watanabe, Hiroki Yamaguchi, Sakae Tanosaki, Takashi Shimada, Kazuo Dan
Journal: Blood (2004)
Abstract P1-02-14: Circulating cell-free DNA (CFD) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study (NCT02001519, NCT02001506)
Authors: K Park, M Woo, JE Kim, J-H Ahn, KH Jung, S-B Kim
Journal: Cancer Research (2017)

Abstract Background: Prior technique to measure cell free DNA(CFD) is labor-intensive and expensive, while, recently developed fluorescent CFD assay is more simple and convenient.The aim of this study was to evaluate the role of CFD measured by a fluorescent assay as a biomarker of patients with triple negative breast cancer (TNBC) received neoadjuvant chemotherapy Methods: We prospectively enrolled patients with TNBC, clinical stage II or III (T&amp;gt;1.5cm or lymph node &amp;gt; 1.5cm), who were scheduled for neoadjuvant chemotherapy. Patients received 4 cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (AC) followed by 4 cycles of cisplatin or docetaxel, and surgery. Plasma samples were obtained from patients before initial chemotherapy (baseline-CFD) and after 4 cycles of AC neoadjuvant chemotherapy (AC-CFD). Results: This study included 72 patients who met the inclusion criteria. The mean levels of baseline-CFD and AC-CFD were 239±68 ng/mL and 210±66 ng/mL, respectively, and the CFD level was significantly decreased after AC chemotherapy.( p=0.001) The baseline-CFD was not associated with initial tumor characteristics. (T stage 1-2 vs. 3, p=0.313; N stage 0 vs. 1-3, p=0.317) There was no statistically significant difference between patients with response (CR or PR) to AC chemotherapy and those without response in terms of baseline-CFD, AC-CFD, and change of CFD between two values. (p=0.814, p=0.839, p=0.927) With 33.6 months of median follow up, there were 18 cases of relapse. Relapsed group showed numerically higher level of baseline-CFD, although it was not statistically significant. (relapse, 259 ng/mL; non-relapse, 233 ng/mL; p=0.161) We performed a ROC curve analysis of baseline-CFD for relapse, and found an area under the curve of 0.62 (95% CI, 0.46-0.78) at 222 ng/mL. Patients with baseline-CFD above 222 showed higher relapses than those below 222. (HR, 2.75; 95% CI, 0.96-7.84; p = 0.059) Conclusions: The baseline-CFD obtained using a simple and convenient fluorescent assay could predict relapse, suggesting baseline-CFD as a potential biomarker for risk stratification of TNBC. Citation Format: Park K, Woo M, Kim JE, Ahn J-H, Jung KH, Kim S-B. Circulating cell-free DNA (CFD) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study (NCT02001519, NCT02001506) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-14.
Use of a Super-Saturated Calcium Phosphate Mouth Rinse for Prevention and Treatment of Oral Mucositis Results In Faster Granulocyte Recovery and Hospital Discharge Than Using a Sodium Bicarbonate Rinse Alone After Autologous Transplantation In the Treatment of Lymphoma.
Authors: Ilana Yablonovich, Michele L Donato, Andrew L Pecora, Stuart L Goldberg, Tatyana Feldman, Andre Goy, Anthony R Mato, Scott D Rowley
Journal: Blood (2010)
Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis
Authors: Francesca Palandri, Nicola Polverelli, Roberto Latagliata, Alessia Tieghi, Emanuela Ottaviani, Monica Crugnola, Margherita Perricone, Bruno Martino, Giuliana Alimena, Francesco Merli, Franco Aversa, Lucia Catani, Michele Cavo, Giovanni Martinelli, Nicola Vianelli
Journal: Blood (2014)
Prenatal Nutritional Deficiency and Psychosis
Authors: Ezra Susser, Katherine M. Keyes
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Teenager With Hip Pain and Limp
Authors: Nicole Sheanon, Blair Simpson, Erin Shaughnessy
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Authors: Catherine Garnett, Chrissy Giles, Maialen Lasa, Osman Ahmed, Marco Bua, Holger W. Auner, Donald MacDonald, Sasha Marks, David Marin, Dragana Milojkovic, Jiri Pavlu, Saad Abdalla, Edward J Kanfer, Jane Apperley, Amin Rahemtulla
Journal: Blood (2012)
Reperfusion Shutdown: Delayed Onset of Fibrinolysis Resistance after Resuscitation from Hemorrhagic Shock Is Associated with Increased Circulating Levels of Plasminogen Activator Inhibitor-1 and Postinjury Complications
Authors: Hunter B Moore, Ernest E Moore, Eduardo Gonzalez, Benjamin J Huebner, Forest Sheppard, Anirban Banerjee, Angela Sauaia, Christopher C. Silliman
Journal: Blood (2016)
Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter
Authors: Yohann Repesse, Ivan Peyron, Jordan Dimitrov, Suryasarathi Dasgupta, Elika Farrokhi Moshai, Annie Borel-Derlon, Catherine Costa, Benoist Guillet, Roseline d'Oiron, Achille Aouba, Chantal Rothschild, Johannes Oldenburg, Ana Pavlova, Srinivas Kaveri, Sebastien Lacroix-Desmazes
Journal: Blood (2012)
Valproic Acid Results In Maintenance but Not Expansion of Transplantable Hematopoietic Stem Cells From Human Umbilical Cord Blood
Authors: Hiroto Araki, Sudhakar Baluchamy, Benjamin Petro, Mirza Saqib Baig, Montha Suhangul, John G. Quigley, Naoyuki Katayama, Nadim Mahmud
Journal: Blood (2010)
OP03. GENOMICS ENGLAND’S 100,000 GENOME PROJECT: WHERE DO BRAIN TUMOURS FIT IN?
Authors: Prof Keyoumars Ashkan, Prof Richard Houlston
Journal: Neuro-Oncology (2017)

AUTHORS: K Ashkan and R Houlston on behalf of Glioma GeCIP AIM: to update the UK’s neuro-oncology community on Genomics England’s 100,000 Genome Project and the implications for patients with brain tumours. BACKGROUND: In 2013 Genomics England committed to whole genome sequencing of 100,000 genomes in patients with rare diseases, including cancers. The four stated aims were: bringing benefit to NHS patients, creating an ethical and transparent programme based on consent, enabling new scientific discovery and medical insight, and kick starting the development of a UK genomics industry. The project is supported by the 13 NHS Genomic Medical Centres, NIHR National Biosample Centre and Illumina NHS Genomic Medicine Sequencing Centre. Central to the project is the concept of Genomic England Clinical Interpretation Partnership (GeCIP) to prioritise and address clinical questions from the genomic data generated to maximise benefit to the patients. The first wave of the project in 2014 adopted commoner cancers namely cancers of breast, lung, prostate, large bowel, ovaries and CLL. In late 2015, we campaigned for adoption of primary brain tumours into the programme, given our strong belief that such research was urgently required and was likely to yield clinically important information. In early 2016, Genomics England agreed to the adoption of adult gliomas into the programme as well as a number of other primary brain tumours. METHODS: In this talk the current status of Genomics England’s 100,000 Genome Project as applied to the brain tumours is discussed. The steps required to set up and start the project in the various neurosurgery/ neuro-oncology centres across the UK are illustrated. The processes involved in accessing and translating the genomic data generated to address clinically relevant questions are described. CONCLUSION: Genomics England’s 100,000 Genome Project represents a great opportunity to obtain unique data with real potential for patient benefit. Involvement of neurosurgery/ neuro-oncology centres across the UK is essential to maximise this potential.
Abstract P1-10-17: Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer
Authors: A Dautruche, L Belin, P Cottu, P Bontemps, C Lemanski, B De La Lande, P Baumann, F Missohou, C Levy, K Peignaux, A Reynaud-Bougnoux, F Denis, A Gobillion, N Ady Vago, A Fourquet, Y Kirova
Journal: Cancer Research (2017)

Abstract Purpose/Objectives The purpose of this study was to determine early and late toxicities among patients with non-metastatic breast cancer (BC) receiving concurrent bevacizumab (BV) and radiation therapy (RT). Materials/Methods Multicentre, prospective study, of the toxicity of adjuvant concomitant association of BV and RT in patients with non-metastatic BC enrolled in Phase 3 BEATRICE, BEVERLY and BETH trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during RT, 12 months and 36 months after its completion. Results Sixty-four patients were included from october 2007 to august 2010. They all received adjuvant RT and BV concomitant treatment, plus neo-adjuvant BV for 24 patients. RT was adjuvant and normo-fractionated. Twelve months toxicity was available for 60 patients and 36 months toxicity was available for 43 patients. Median follow-up was 46 months (18-77). Median age was 51 years old (23-68). Among 63 evaluated patients during RT, acute radiation dermatitis was observed in 48 (76%) patients : Grade 1 for 27 (43%), grade 2 for 17 (27%), grade 3 for 4 patients (6%). Grade 2 acute oesophagitis was observed in 1 patient. At 3 years, few toxicities were observed : 6 patients (14%) had grade 1 pain, 4 (9%) had grade 1 fibrosis, one (2%) had grade 1 telangiectasis, one (2%) had grade 1 paresis, 3 (7%) had grade 1 lymphoedema and one grade 3 lymphoedema. No grade 4 toxicity was observed. At 12 months, only one evaluated patient had a LVEF &amp;lt;50% and none at 36 months. Conclusions Concurrent bevacizumab with locoregional RT is associated with acceptable early and late 3-years toxicities in patients with BC. Determination of late toxicity at 60 months is currently underway. Citation Format: Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-10-17.
Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study
Authors: Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy
Journal: Blood (2016)
Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).
Authors: C. Kelaidi, L. Ades, S. Chevret, M. A. Sanz, A. Guerci, X. Thomas, S. de Botton, E. Raffoux, C. Rayon, J. de la Serna, A. Ferrant, D. Bron, H. Link, N. Fegueux, D. Bordessoule, F. Rigal-Huguet, A.M. Stoppa, A. Vekhoff, S. Meyer-Monard, M. Fey, S. Castaigne, H. Dombret, L. Degos, P. Fenaux
Journal: Blood (2005)